{"podcast":{"title":"The NextGen VC Podcast","slug":"the-nextgen-vc-podcast-6617779","podcast_index_feed_id":6617779,"rss_url":"https://anchor.fm/s/e77f3ea0/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/nextgenvcpodcast","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38738760/38738760-1693942072183-3e001a56cd566.jpg","author":"LaunchBio","episode_count":24,"summary":"The NextGen VC Podcast is the premier podcast for forward-thinking venture capitalists eager to dive in and sharpen their skills. It unpacks the opportunities, challenges, and breakthroughs shaping life sciences investing today, and is curated by Wilson Sonsini and LaunchBio with hosts Michael Hostetler and Jen Fang. Email the show: questions@launchbio.org Learn about in-person NextGen VC events: launchbio.org/programs/nextgen-vc-forum/ Discover resources for the life sciences community: launchbio.org","last_synced_at":"2026-07-08T02:17:43.433949+00:00","page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779"},"episode":{"title":"The $2.25B Exit That Changed Lumira's Investment Strategy","slug":"the-2-25b-exit-that-changed-lumira-s-investment-strategy","published_at":"2026-06-08T17:36:03+00:00","page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/the-2-25b-exit-that-changed-lumira-s-investment-strategy","show_page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779","url":"https://podcasters.spotify.com/pod/show/nextgenvcpodcast/episodes/The-2-25B-Exit-That-Changed-Lumiras-Investment-Strategy-e3kgp16","audio_url":"https://anchor.fm/s/e77f3ea0/podcast/play/121184742/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-8%2F425748048-44100-2-c54b32f8b1c07.mp3","summary":"Jen and Mike sit down with Dr. Suman Rao, Principal at Lumira Ventures, to discuss her path from academic science to healthcare venture capital and why she believes the best investors lead with mission before money. Rao shares Lumira’s approach to investing beyond traditional biotech hubs, the firm’s sidecar fund model with partners like Merck and the Terry Fox Foundation, and the story behind Histosonics, a Midwest medtech company that grew into a $2.25B exit and helped shape Lumira’s next investment thesis. She also offers candid advice for aspiring VCs: don’t follow the prescribed path. Build your own.","meta_description":"Jen and Mike sit down with Dr. Suman Rao, Principal at Lumira Ventures, to discuss her path from academic science to healthcare venture capital and why sh…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2842,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-nextgen-vc-podcast-6617779/episodes/the-2-25b-exit-that-changed-lumira-s-investment-strategy/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/the-2-25b-exit-that-changed-lumira-s-investment-strategy.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}